Loading clinical trials...
Loading clinical trials...
A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677
The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
Yes
Anaheim Clinical Trials, LLC
Anaheim, California, United States
ICON Early Phase Services
San Antonio, Texas, United States
ICON Early Phase Services Lenexa Center
Salt Lake City, Utah, United States
Start Date
November 16, 2022
Primary Completion Date
June 27, 2023
Completion Date
June 27, 2023
Last Updated
July 5, 2023
32
ACTUAL participants
LY3305677
DRUG
Placebo
DRUG
Lead Sponsor
Eli Lilly and Company
NCT07472881
NCT01143454
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions